Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2015-10-31
2017-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery
NCT05275218
Biomarker-guided Implementation of the AKI Bundle
NCT03244514
Proenkephalin A and Kidney Replacement Therapy
NCT04879706
Biomarker-guided Intervention to Prevent Acute Kidney Injury
NCT04647396
AKI Prevention and Early Intervention in Patients Undergoing VAD Placement
NCT03236831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
kidney treatment bundle (KDIGO)
Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
kidney treatment bundle (KDIGO)
Application of the measures of the kidney treatment bundle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
kidney treatment bundle (KDIGO)
Application of the measures of the kidney treatment bundle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic kidney disease
* diabetes mellitus, chronic heart, lung or liver disease
* hemodynamic instability (intra and/or post-operative)
* trauma, burn injury, major surgery, usage of x-ray contrast and sepsis.
Exclusion Criteria
* pregnancy
* kidney graft recipient
* chronic renal disease with or without renal replacement therapy and cardiac surgery.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuerzburg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Christian Wunder
Vice chair and leading senior physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Wunder, MD
Role: PRINCIPAL_INVESTIGATOR
University of Wuerzburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Wuerzburg, Dep. of Anesthesiology
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
022015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.